Safety Assessment of an Anti-Obesity Drug (Sibutramine)A Retrospective Cohort Study

被引：0
作者：
Jerzy E. Tyczynski
Denise M. Oleske
David Klingman
Cheryl P. Ferrufino
Won Chan Lee
机构：
[1] Product Safety and Pharmacovigilance,Astellas Pharma Global Development, Inc.
[2] Global Surveillance and Pharmacoepidemiology,Abbott Laboratories
[3] Dept R4ED,Health Economics and Outcomes Research
[4] IMS Health Inc.,undefined
来源：
Drug Safety | 2012年 / 35卷 / 8期
关键词：
Acute Myocardial Infarction; Orlistat; Rimonabant; Sibutramine; Label Status;
D O I：
10.1007/BF03261960
中图分类号：
学科分类号：
摘要：
Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns over the potential of increased risk of cardiovascular (CV) events, based on a phase IV clinical trial that included only individuals at high risk for CV events.
引用
收藏
页码：629 / 644
页数：15
相关论文
共 62 条
  • [1] James P.T.(2004)The obesity epidemic, metabolic syndrome and future prevention strategies Eur J Cardiovasc Prev Rehabil Feb 11 3-8
  • [2] Rigby N.(2009)The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis BMC Public Health 9 88-20C
  • [3] Leach R.(2010)Prevention of cardiovascular disease: obesity, diabetes and the metabolic syndrome Can J Cardiol 26 18-4
  • [4] Guh D.P.(2007)Endocannabinoid system and cardiometabolic risk Clin Pharmacol Ther 82 591-102
  • [5] Zhang W.(2007)The epidemiology of obesity Gastroenterology 132 2087-7
  • [6] Bansback N.(2010)The epidemiology of obesity Gastroenterol Clin North Am 39 1-70
  • [7] Padwal R.S.(1996)A double-blind randomized placebo-controlled trial of sibutramine Obes Res 4 263-25
  • [8] Sharma A.M.(2000)Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet 356 2119-94
  • [9] Saavedra L.E.(2010)Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period Obesity (Silver Spring) 18 987-17
  • [10] Ogden C.L.(2010)Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects N Engl J Med 363 905-402
1234567